Invesco Ltd. Avrobio, Inc. Transaction History

Invesco Ltd.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.75 - $1.33 $8,571 - $15,200	-11,429 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$1.29 - $4.04 $50 - $157	39 Added 0.34%	11,429 $15,000
Q4 2021 Feb 14, 2022	SELL	$3.45 - $6.05 $25,647 - $44,975	-7,434 Reduced 39.49%	11,390 $44,000
Q3 2021 Nov 15, 2021	BUY	$5.53 - $9.28 $10,202 - $17,121	1,845 Added 10.87%	18,824 $105,000
Q2 2021 Aug 17, 2021	BUY	$7.84 - $12.6 $133,115 - $213,935	16,979 New	16,979 $151,000
Q1 2020 May 15, 2020	SELL	$10.08 - $27.21 $1.44 Million - $3.89 Million	-143,119 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$14.12 - $23.44 $77,631 - $128,873	-5,498 Reduced 3.7%	143,119 $2.02 Million
Q2 2019 Aug 14, 2019	BUY	$13.21 - $27.29 $72,734 - $150,258	5,506 Added 3.85%	148,617 $2.42 Million
Q1 2019 May 15, 2019	SELL	$12.46 - $22.05 $2,703 - $4,784	-217 Reduced 0.15%	143,111 $3.16 Million
Q4 2018 Feb 14, 2019	BUY	$15.43 - $32.7 $2.21 Million - $4.69 Million	143,328 New	143,328 $2.39 Million

559K

Ticker AVRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,773,900
Description
AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the...

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

Stay updated on Invesco Ltd. with notifications on news.